Corvidia raises $26M, licenses cardio candidate
Summary
Corvidia Therapeutics raised $26 million in a Series A financing led by Sofinnova Partners and Apple Tree Partners. The company also licensed the cardiovascular monoclonal antibody COR-001 from AstraZeneca. Corvidia plans to advance COR-001 into a Phase I/II trial for cardiovascular disease. The deal signals continued investment in life sciences R&D and clinical development assets.
Funding
Amount
$26.0M
Total raised
Date
February 18, 2016
Announcement date
Investors
Amylin Pharmaceuticals, Apple Tree Partners
Lead investors
Company
corvidia.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected